NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 23 04:00PM ET
5.81
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-1.34 Insider Own11.43% Shs Outstand48.95M Perf Week-5.68%
Market Cap297.22M Forward P/E41.50 EPS next Y0.14 Insider Trans-2.04% Shs Float45.31M Perf Month-9.92%
Enterprise Value236.71M PEG- EPS next Q-0.38 Inst Own59.25% Short Float13.26% Perf Quarter12.82%
Income-44.19M P/S- EPS this Y66.99% Inst Trans-2.37% Short Ratio3.55 Perf Half Y-1.19%
Sales0.00M P/B6.87 EPS next Y127.36% ROA-50.73% Short Interest6.01M Perf YTD4.31%
Book/sh0.85 P/C3.52 EPS next 5Y- ROE-271.78% 52W High7.32 -20.67% Perf Year27.97%
Cash/sh1.65 P/FCF- EPS past 3/5Y58.40% 47.21% ROIC-78.05% 52W Low3.93 47.73% Perf 3Y43.72%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility1.14% 2.31% Perf 5Y-92.58%
Dividend TTM- EV/Sales- EPS Y/Y TTM72.26% Oper. Margin- ATR (14)0.35 Perf 10Y-96.83%
Dividend Ex-Date- Quick Ratio4.90 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)42.53 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio4.90 EPS Q/Q79.10% SMA20-6.61% Beta1.54 Target Price19.93
Payout- Debt/Eq0.58 Sales Q/Q- SMA50-0.49% Rel Volume0.00 Prev Close5.81
Employees136 LT Debt/Eq0.37 EarningsMay 15 BMO SMA2000.85% Avg Volume1.69M Price5.81
IPOSep 19, 1980 Option/ShortYes / Yes EPS/Sales Surpr.32.96% - Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jun-02-25Resumed Oppenheimer Outperform $19
Mar-05-25Initiated Oppenheimer Outperform $16
Jul-03-24Initiated H.C. Wainwright Buy $15
May-30-24Initiated Stifel Buy $21
Nov-11-20Upgrade Cantor Fitzgerald Neutral → Overweight $4
Sep-18-20Initiated B. Riley FBR Buy $5
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Today 07:30AM
Jun-02-25 07:30AM
May-30-25 08:46AM
May-15-25 07:38AM
07:30AM
08:07AM Loading…
May-14-25 08:07AM
07:30AM
07:30AM
May-13-25 07:21AM
May-12-25 07:30AM
04:38AM
May-07-25 04:59PM
Apr-30-25 07:16AM
Apr-29-25 03:06PM
06:00AM
08:30AM Loading…
Apr-27-25 08:30AM
Apr-21-25 10:00AM
Apr-14-25 07:11AM
Apr-12-25 11:39AM
Apr-06-25 08:38AM
Apr-01-25 07:30AM
Mar-21-25 03:02AM
12:41AM
Mar-20-25 03:21PM
03:20PM
07:30AM
Mar-04-25 09:00AM
07:46AM
Mar-03-25 07:30AM
Feb-03-25 07:30AM
07:30AM Loading…
Dec-31-24 07:30AM
Dec-02-24 07:30AM
Nov-27-24 07:00AM
Nov-15-24 02:06AM
Nov-14-24 07:42AM
07:30AM
Nov-12-24 07:30AM
Nov-04-24 07:30AM
Nov-01-24 07:30AM
Oct-29-24 07:30AM
Oct-09-24 06:13PM
Oct-01-24 07:30AM
Sep-03-24 07:30AM
Sep-02-24 07:30AM
Aug-14-24 07:30AM
Aug-13-24 07:30AM
Aug-12-24 07:37AM
07:30AM
Aug-01-24 07:30AM
Jul-11-24 07:30AM
Jul-08-24 07:30AM
Jun-21-24 03:08AM
Jun-03-24 07:30AM
May-28-24 07:30AM
May-16-24 03:01AM
02:17AM
May-15-24 12:53PM
07:43AM
07:30AM
May-07-24 07:30AM
May-03-24 11:19AM
07:30AM
Apr-23-24 02:04PM
08:53AM
07:39AM
07:09AM
Apr-22-24 05:58PM
04:27PM
04:14PM
04:05PM
Apr-01-24 08:30AM
Mar-19-24 06:53AM
05:31AM
Mar-18-24 07:30AM
Mar-05-24 07:30AM
Feb-15-24 05:52AM
Feb-01-24 04:05PM
07:30AM
Jan-08-24 07:30AM
Dec-15-23 07:30AM
Nov-27-23 07:30AM
Nov-17-23 10:09AM
Nov-14-23 04:29AM
Nov-13-23 12:23PM
07:41AM
07:30AM
Nov-01-23 07:30AM
Sep-26-23 07:30AM
Sep-12-23 12:48PM
07:30AM
Sep-07-23 07:30AM
Aug-30-23 07:30AM
Aug-11-23 07:41AM
Aug-08-23 08:27AM
07:30AM
Jul-28-23 07:30AM
Jul-19-23 08:30AM
Jul-07-23 08:30AM
Jul-03-23 08:45AM
Jun-09-23 07:30AM
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vazzano Joseph WalterChief Financial OfficerJun 06 '25Sale6.7617,795120,294491,246Jun 06 06:04 PM
Seshadri VishwasChief Executive OfficerJun 06 '25Sale6.7650,676342,5701,303,761Jun 06 06:00 PM
O'Malley Brendan M.SVP, General CounselJun 06 '25Sale6.7610,47070,777378,245Jun 06 05:56 PM
Vazzano Joseph WalterOfficerJun 06 '25Proposed Sale6.7617,795120,314Jun 06 04:13 PM
O'Malley Brendan M.DirectorJun 06 '25Proposed Sale6.7610,47070,789Jun 06 04:12 PM
Seshadri VishwasOfficerJun 06 '25Proposed Sale6.7650,676342,626Jun 06 04:11 PM
Alvino MarkDirectorMay 27 '25Sale6.382,00012,76090,435May 27 07:57 PM
Alvino MarkDirectorMay 27 '25Proposed Sale6.382,00012,762May 27 04:40 PM
Alvino MarkDirectorMay 16 '25Sale5.688,00045,44092,435May 16 05:23 PM
Alvino MarkDirectorMay 16 '25Proposed Sale5.688,00045,423May 16 04:07 PM
Seshadri VishwasChief Executive OfficerMar 31 '25Sale4.7825,000119,5001,355,322Mar 31 07:17 PM
Seshadri VishwasOfficerMar 31 '25Proposed Sale4.7825,000119,560Mar 31 04:08 PM
Alvino MarkDirectorJan 29 '25Sale5.384,00021,52064,334Jan 31 04:30 PM
Alvino MarkOfficerJan 29 '25Proposed Sale5.414,00021,640Jan 29 04:03 PM
Alvino MarkDirectorJan 21 '25Sale5.104,00020,40068,334Jan 21 04:30 PM
Alvino MarkOfficerJan 21 '25Proposed Sale5.224,00020,880Jan 21 04:05 PM